Molecular structure, spectroscopic (FT-IR, NMR and UV–Vis), electronic properties, molecular docking, and molecular dynamics studies on novel thiazolidinone derivative: A potent breast cancer drug

• Published in: Journal of molecular structure Vol. 1318; p. 139301
• Main Authors: Koyambo-Konzapa, Stève-Jonathan, Oubella, Ali, Issaoui, Noureddine, Amolo, George, Taha, Mohamed Labd, Geesi, Mohammed H., Aldakhil, Taibah, Riadi, Yassine, Auhmani, Aziz, Itto, My Youssef Ait
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 15.12.2024
• Subjects: (R)-Camphor; DFT; IR spectroscopy, RMN spectroscopy, Molecular docking, Molecular dynamics; Thiazolidinone; DFT; (R)-Camphor; Thiazolidinone; IR spectroscopy, RMN spectroscopy, Molecular docking, Molecular dynamics
• ISSN: 0022-2860
• DOI: 10.1016/j.molstruc.2024.139301

•A novel compound of thiazolidinone was synthesised, characterized.•The vibrational modes of thiazolidinone were investigated.•The electronic properties were examined gas phase and chloroform solvent.•Inhibitory nature of thiazolidinone against breast cancer were predicted.•Molecular dynamics analysis confirms the reliability of the docking poses. This study details the synthesis, characterization, and comprehensive computational analysis of a novel (R)-camphor-based thiazolidinone derivative. The structural integrity of the synthesized compound was confirmed using 1H- and 13CNMR spectroscopy as well as HRMS. Theoretical vibrational modes were successfully assigned and matched well with the observed FT-IR spectrum. Simulated NMR values were in excellent agreement with experimental chemical shifts, showing maximum deviations of less than 1.5 ppm for 1H and 4 ppm for 13C. UV–vis spectroscopy revealed n→π* and π→π* transitions in thiazolidinone, with intermolecular charge transfer (ICT) corroborated by Frontier Molecular Orbital (FMO), density of states (DOS), and Natural Bond Orbital (NBO) analyses. Molecular docking studies indicated that thiazolidinone exhibited strong inhibitory activity against the breast cancer target protein 6HQO, which was further validated by molecular dynamics simulations, confirming the stability and accuracy of the docking results. [Display omitted]